ReviewNature reviews. Urology2019
Cancer metabolomic markers in urine: evidence, techniques and recommendations.
Review in Nature reviews. Urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06710067 (Observational Study of Urine Metabolites in the Diagnosis of Disease), which is not on this map. Cited by 78 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Observational Study of Urine Metabolites in the Diagnosis of Disease
Who cites it
78 citing papers in PubMed, 1 synthesis or guideline pooled it, 159 citations in OpenAlex.
- Metabolomic profile and its association with the diagnosis of prostate cancer: a systematic review.Journal of cancer research and clinical oncology · 2024Pooled it
- Advances in urinary biomarkers for endometrial cancer detection.British journal of cancer · 2026Review
- MALDI Matrix: Origins, Innovations, and Frontiers.Chemical reviews · 2026Review
- Exploring metabolic signatures in urine using NMR for improved prognosis of gliomas.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- Article
- A repository of the salivary metabolome and its key drivers in 1436 European children.EBioMedicine · 2025Article
- Article
- A Comparative Metabolomics Study of Multiple Urological Diseases by Highly Sensitive Dansylation Isotope Labeling LC-MS.International journal of molecular sciences · 2025Article
- Exploring the role of 338 cerebrospinal fluid metabolites in primary brain malignancies risk: a Mendelian randomization study.Discover oncology · 2025Article
- Volatile organic compounds (VOCs) detection for the identification of bacterial infections in clinical wound samples.Talanta · 2025Review
- Untargeted metabolomic profiling of serum and urine in kidney cancer: a non-invasive approach for biomarker discovery.Metabolomics : Official journal of the Metabolomic Society · 2025Article
- Article
- Identification of Diagnostic Biomarkers for Colorectal Polyps Based on Noninvasive Urinary Metabolite Screening and Construction of a Nomogram.Cancer medicine · 2025Article
- Exploring the complex relationship between metabolomics and breast cancer early detection (Review).Molecular and clinical oncology · 2025Review
- Predicting Clinically Significant Prostate Cancer Using Urine Metabolomics via Liquid Chromatography Mass Spectrometry.The world journal of men's health · 2025Article
- "Three-in-one" Analysis of Proteinuria for Disease Diagnosis through Multifunctional Nanoparticles and Machine Learning.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Malignant Transformed and Non-Transformed Oral Leukoplakias Are Metabolically Different.International journal of molecular sciences · 2025Article
- Novel Biomarkers for Early Detection of Hepatocellular Carcinoma.Diagnostics (Basel, Switzerland) · 2024Review
- Data privacy-aware machine learning approach in pancreatic cancer diagnosis.BMC medical informatics and decision making · 2024Article
- The role of dysregulated metabolism and associated genes in gastric cancer initiation and development.Translational cancer research · 2024Review
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
Abstract
Urinary tests have been used as noninvasive, cost-effective tools for screening, diagnosis and monitoring of diseases since ancient times. As we progress through the 21st century, modern analytical platforms have enabled effective measurement of metabolites, with promising results for both a deeper understanding of cancer pathophysiology and, ultimately, clinical translation. The first study to measure metabolomic urinary cancer biomarkers using NMR and mass spectrometry (MS) was published in 2006 and, since then, these techniques have been used to detect cancers of the urological system (kidney, prostate and bladder) and nonurological tumours including those of the breast, ovary, lung, liver, gastrointestinal tract, pancreas, bone and blood. This growing field warrants an assessment of the current status of research developments and recommendations to help systematize future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.